Filters








1,462 Hits in 6.2 sec

Modeling brain‐predicted age from functional connectivity in early‐stage and preclinical Alzheimer disease

Peter R Millar, Patrick H Luckett, Tammie L.S. Benzinger, Anne M. Fagan, John C. Morris, Beau M. Ances
2021 Alzheimer's & Dementia  
Advanced brain-predicted age has been observed in many studies of symptomatic Alzheimer disease (AD), but the effects of preclinical AD have not been investigated.  ...  Here we modeled FC-predicted brain age and tested its relationships with preclinical and symptomatic AD.  ...  FC-predicted brain age may be a sensitive biomarker in future models of healthy aging and symptomatic AD. F  ... 
doi:10.1002/alz.056280 fatcat:ofw42nzpp5dpnmomg2efwbx6pq

EFFECTS OF GENE MUTATION AND DISEASE PROGRESSION ON THE STRUCTURE AND FUNCTION OF THREE CORTICO-SUBCORTICAL NEURAL CIRCUITS IN FAMILIAL ALZHEIMER'S DISEASE

Meina Quan, Tan Zhao, Qi Qin, Yi Tang, Jianping Jia
2019 Alzheimer's & Dementia  
We have recently proposed a biphasic trajectory of imaging biomarkers in sporadic Alzheimer's disease and in a small cohort of Autosomal Dominant Alzheimer Disease(ADAD) with an early preclinical phase  ...  : meina_quan@hotmail.comBackground:Changes of brain structure and function are present in symptomatic stages of familial Alzheimer's disease (FAD).PCC.For DTI, tractography was used to obtain 3 tracts  ...  Crosssectional studies in symptomatic AD have shown that flortaucipir (FTP)-PET signal is associated with cognitive decline and atrophy (Hall, B, Ageing Research Reviews, 2017).  ... 
doi:10.1016/j.jalz.2019.06.4501 fatcat:qmx2guk3fvbkvcusfpgcezhueq

Falls: a marker of preclinical Alzheimer disease: a cohort study protocol

Rebecca M Bollinger, Audrey Keleman, Regina Thompson, Elizabeth Westerhaus, Anne M Fagan, Tammie LS Benzinger, Suzanne E Schindler, Chengjie Xiong, David Balota, John C Morris, Beau M Ances, Susan L Stark
2021 BMJ Open  
IntroductionProgression to symptomatic Alzheimer disease (AD) occurs slowly over a series of preclinical stages.  ...  at the Knight Alzheimer Disease Research Center.  ...  Acknowledgements We would like to thank the Knight Alzheimer Disease Research Center staff and all of our participants for making this study possible.  ... 
doi:10.1136/bmjopen-2021-050820 pmid:34526343 pmcid:PMC8444237 fatcat:e5l6yeb4mng63i2si4t2girpau

BIPHASIC TRAJECTORY OF CHANGES FOR CORTICAL THICKNESS AND CORTICAL MEAN DIFFUSIVITY IN AUTOSOMAL-DOMINANT ALZHEIMER'S DISEASE

Victor Montal, Eduard Vilaplana, Jordi Pegueroles, Daniel Alcolea, Johannes Levin, Tammie L.S. Benzinger, Randall Bateman, Jordi Clarimon, Rafael Blesa, Alberto Lleó, Raquel Sanchez-Valle, Juan Fortea
2019 Alzheimer's & Dementia  
Contact e-mail: meina_quan@hotmail.com Background: Changes of brain structure and function are present in symptomatic stages of familial Alzheimer's disease (FAD).  ...  We have recently proposed a biphasic trajectory of imaging biomarkers in sporadic Alzheimer's disease and in a small cohort of Autosomal Dominant Alzheimer Disease(ADAD) with an early preclinical phase  ... 
doi:10.1016/j.jalz.2019.06.4500 fatcat:qnaqdrpdmze25i2cgasdk4vrsi

Sleep and Alzheimer disease pathology—a bidirectional relationship

Yo-El S. Ju, Brendan P. Lucey, David M. Holtzman
2013 Nature Reviews Neurology  
Factors other than age and genetics may increase the risk of developing Alzheimer disease (AD).  ...  Thus, sleep and neurodegenerative disease may influence each other in many ways that have important implications for the diagnosis and treatment of AD.  ...  Ju from the National Center for research resources (UL1 rr024992), which is a component of the NIH, and the NIH roadmap for Medical research.  ... 
doi:10.1038/nrneurol.2013.269 pmid:24366271 pmcid:PMC3979317 fatcat:wshy6d4q45gypawzol7edkzfai

Dominantly Inherited Alzheimer Network: facilitating research and clinical trials

Krista L Moulder, B Snider, Susan L Mills, Virginia D Buckles, Anna M Santacruz, Randall J Bateman, John C Morris
2013 Alzheimer's Research & Therapy  
The Dominantly Inherited Alzheimer Network (DIAN) is an international registry of individuals at risk for developing autosomal dominant Alzheimer's disease (AD).  ...  Its primary aims are to investigate the temporal ordering of AD pathophysiological changes that occur in asymptomatic mutation carriers and to identify those markers that herald the transition from cognitive  ...  the German Center for Neurodegenerative Diseases (DZNE), and a grant from an anonymous foundation.  ... 
doi:10.1186/alzrt213 pmid:24131566 pmcid:PMC3978584 fatcat:aoddoeqb5zcp5ifz2vhevjybve

Developing an international network for Alzheimer's research: the Dominantly Inherited Alzheimer Network

John C Morris, Paul S Aisen, Randall J Bateman, Tammie LS Benzinger, Nigel J Cairns, Anne M Fagan, Bernardino Ghetti, Alison M Goate, David M Holtzman, William E Klunk, Eric McDade, Daniel S Marcus (+15 others)
2012 Clinical Investigation  
DIAN collects comprehensive information and tissue in accordance with standard protocols from asymptomatic and symptomatic ADAD mutation carriers and their non-carrier family members to determine the pathochronology  ...  The Dominantly Inherited Alzheimer Network (DIAN) is a collaborative effort of international Alzheimer disease (AD) centers that are conducting a multifaceted prospective biomarker study in individuals  ...  in the manuscript apart from those disclosed.  ... 
doi:10.4155/cli.12.93 pmid:23139856 pmcid:PMC3489185 fatcat:lkpci2z5yzg6pafx5u66wodjny

The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview

P.S. Aisen, R.A. Sperling, J. Cummings, M.C. Donohue, O. Langford, G.A. Jimenez-Maggiora, R.A. Rissman, M.S. Rafii, S. Walter, T. Clanton, R. Raman
2020 The journal of prevention of Alzheimer's disease  
The Webstudy data is used to predict the likelihood of brain amyloid elevation; individuals at relatively high risk are invited for in-person assessment in the TRC screeing phase, during which a cognitive  ...  Clinically normal and mildly symptomatic individuals are followed longitudinally in a web-based component called the Alzheimer's Prevention Trial Webstudy (APT Webstudy), with quarterly assessment of cognition  ...  The Trial-Ready Cohort in Preclinical/prodromal Alzheimer's disease (TRC-PAD) program grew out of a series of meetings of academic and industry investigators, organized by the Global Alzheimer Platform  ... 
doi:10.14283/jpad.2020.45 pmid:32920621 pmcid:PMC7735207 fatcat:akh7noothfbuto4cud64lyqfkm

THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME

Juan Fortea, Eduard Vilaplana, Maria Carmona-Iragui, Bessy Benejam, Susana Fernandez, Laura Videla, Isabel Barroeta, Miren Altuna, Daniel Alcolea, Jordi Pegueroles, Victor Montal, Laia Muñoz-Llahuna (+9 others)
2019 Alzheimer's & Dementia  
Contact e-mail: meina_quan@hotmail.com Background: Changes of brain structure and function are present in symptomatic stages of familial Alzheimer's disease (FAD).  ...  We have recently proposed a biphasic trajectory of imaging biomarkers in sporadic Alzheimer's disease and in a small cohort of Autosomal Dominant Alzheimer Disease(ADAD) with an early preclinical phase  ... 
doi:10.1016/j.jalz.2019.06.4499 fatcat:v4l2vedribhkhpejwo65p52hvu

SINGLE-SUBJECT GREY MATTER NETWORKS DETERIORATE 12 YEARS BEFORE DEMENTIA

Lisa Vermunt, Betty M. Tijms, Pieter Jelle Visser, Philip Scheltens, Randall Bateman, Tammie L.S. Benzinger, Brian A. Gordon
2019 Alzheimer's & Dementia  
Background: Brain structures involved in particular cognitive functions often co-develop, resulting in similarity in their grey matter structure.  ...  We investigated this question in autosomal dominant AD, where the onset age of dementia is highly predictable, and for whom the estimated years to symptom onset (EYO) can be used as a proxy for disease  ...  Familial Alzheimer's disease (FAD) provides the opportunity to study preclinical change as mutations are 100% penetrant and have a reasonably-consistent age at onset within families.  ... 
doi:10.1016/j.jalz.2019.06.4502 fatcat:ahdgbwkdvjbnrfrqi55lxcitfi

Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease

Jewell B. Thomas, Matthew R. Brier, Randall J. Bateman, Abraham Z. Snyder, Tammie L. Benzinger, Chengjie Xiong, Marcus Raichle, David M. Holtzman, Reisa A. Sperling, Richard Mayeux, Bernardino Ghetti, John M. Ringman (+26 others)
2014 JAMA Neurology  
Ordinal logistic regression models constructed in one type of Alzheimer disease accurately predicted clinical dementia rating scores in the other, further demonstrating the similarity of functional connectivity  ...  We analyzed functional connectivity in multiple brain resting state networks (RSNs) in a cross-sectional cohort of participants with ADAD (n = 79) and LOAD (n = 444), using resting-state functional connectivity  ...  Estimated Years From Onset Within the Dominantly Inherited Alzheimer Network cohort, parent age at symptomatic onset was determined from semistructured interviews with the participant, a knowledgeable  ... 
doi:10.1001/jamaneurol.2014.1654 pmid:25069482 pmcid:PMC4240274 fatcat:hfb542cyxfbqxjtdm3tbwrwgg4

Biomarkers of Alzheimer Disease

Reisa Sperling, Keith Johnson
2013 Continuum. Lifelong Learning in Neurology  
Purpose of Review: This article reviews recent advances in imaging and fluid biomarkers for Alzheimer disease (AD) and their application to newly proposed diagnostic criteria across the continuum of AD  ...  Similarly, new research in CSF markers suggests CSF levels of A" 1j42 and phosphorylated tau may be useful in the early diagnosis of AD and prediction of cognitive decline.  ...  cortical networks, in particular a set of functionally connected brain regions known as the default network, which has been implicated in memory and other com-plex cognitive processes.  ... 
doi:10.1212/01.con.0000429181.60095.99 pmid:23558480 fatcat:iu5w3yza7zb5vebqoutyr4w62e

Functional brain age prediction suggests accelerated aging in preclinical familial Alzheimer's disease, irrespective of fibrillar amyloid-beta pathology [article]

Julie Gonneaud, Alex T Baria, Alexa Pichet Binette, Brian A Gordon, Jasmeer P Chhatwal, Carlos Cruchaga, Mathias Jucker, Johannes Levin, Stephen Salloway, Martin Farlow, Serge Gauthier, Tammie LS Benzinger (+9 others)
2020 bioRxiv   pre-print
We aimed at developing a model able to predict brain aging from resting state functional connectivity (rs-fMRI) and assessing whether genetic risk/determinants of Alzheimer's disease (AD) and amyloid (  ...  Applying our predictive model in the context of preclinical AD revealed that the pre-symptomatic phase of ADAD is characterized by accelerated functional brain aging.  ...  Madjar and all the PREVENT-AD center for participants' recruitment, data acquisition and  ... 
doi:10.1101/2020.05.06.076745 fatcat:a3izfs2cbvcodb5jxih6rh4p3q

Preclinical Alzheimer disease—the challenges ahead

Reisa A. Sperling, Jason Karlawish, Keith A. Johnson
2012 Nature Reviews Neurology  
Keywords aging and dementia, brain imaging, cognitive neurology Abstract There is growing recognition that the pathophysiological process of Alzheimer disease (AD) begins many years prior to clinically  ...  There is growing recognition that the pathophysiological process of Alzheimer disease (AD) begins many years prior to clinically obvious symptoms, and the concept of a presymptomatic or preclinical stage  ...  Johnson is supported in part by the National Institute on Aging (P01 AG036694; P50 AG005134; R01 AG027435; R01 AG037497), the American Health Assistance Foundation, and the Alzheimer's Association.  ... 
doi:10.1038/nrneurol.2012.241 pmid:23183885 pmcid:PMC3643203 fatcat:qpchnkld2zbxvin57bwxd4ltoi

Unrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging

M. R. Brier, J. B. Thomas, A. Z. Snyder, L. Wang, A. M. Fagan, T. Benzinger, J. C. Morris, B. M. Ances
2014 Neurology  
In most regions with significant interactions of age and biomarker status, the age-related change in functional connectivity in the normal biomarker group was indistinguishable from zero.  ...  Objective: To determine whether, and to what degree, preclinical Alzheimer disease (AD) confounds studies of healthy aging where "healthy" is based on cognitive normality alone.  ...  Morris has participated in drug trials with Janssen Immunotherapy, Pfizer, and Eli Lilly, and has received honoraria from the Charles A. Dana Foundation, Eli Lilly, and Eisai. B.  ... 
doi:10.1212/wnl.0000000000000939 pmid:25261500 pmcid:PMC4223085 fatcat:2ybw4jyt2zdsjfuujtokhli3q4
« Previous Showing results 1 — 15 out of 1,462 results